Trial · NCT03241745
A Study of Nivolumab in Selected Uterine Cancer Patients
NCT03241745, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2024-12-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Nivolumab in Selected Uterine Cancer Patients. Trials, record NCT03241745. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03241745
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Nivolumab in Selected Uterine Cancer Patients
- NCT number
- NCT03241745
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 35 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Uterine Cancer, Endometrial Carcinoma, Carcinosarcoma, Leiomyosarcoma, Undifferentiated Sarcoma, High Grade Endometrial Stromal Sarcoma, Clear Cell Carcinoma
- Interventions
- Nivolumab
- First posted
- 2017-08-07
- Last updated
- 2024-12-27
- Results first posted
- 2024-12-27
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival | at 24 weeks | will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-Free Survival | at 24 weeks | percentage of patients | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival | Nivolumab | 64.7 | 97.5% Confidence Interval 46.5 to 100 | percentage of patients |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Nivolumab | 35 | |
| Overall Study | COMPLETED | Nivolumab | 6 | |
| Overall Study | NOT COMPLETED | Nivolumab | 29 |
Source ClinicalTrials.gov
Adverse events164
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal distension | Gastrointestinal disorders | Nivolumab | 2 | 35 | |
| other | Abdominal pain | Gastrointestinal disorders | Nivolumab | 9 | 35 | |
| other | Acute kidney injury | Renal and urinary disorders | Nivolumab | 1 | 35 | |
| other | Acute optic neuritis | Eye disorders | Nivolumab | 1 | 35 | |
| other | Alanine aminotransferase increased | Investigations | Nivolumab | 2 | 35 | |
| other | Alkaline phosphatase increased | Investigations | Nivolumab | 3 | 35 | |
| other | Allergic reaction | Immune system disorders | Nivolumab | 1 | 35 | |
| other | Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | Nivolumab | 1 | 35 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Nivolumab | 3 | 35 | |
| other | Anemia | Blood and lymphatic system disorders | Nivolumab | 4 | 35 |
1 to 10 of 164Source ClinicalTrials.gov
See all 164 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Nivolumab | 14 | 35 |
| Total, other adverse events | Nivolumab | 35 | 35 |
| Total, serious adverse events | Nivolumab | 12 | 35 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38653864 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03241745
GET https://conductscience.org/api/trials/v1/NCT03241745/events?page=2